SELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 9,455 call options on the stock. This represents an increase of approximately 146% compared to the average volume of 3,838 call options.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in SELLAS Life Sciences Group in the 2nd quarter worth $39,000. XTX Topco Ltd bought a new stake in SELLAS Life Sciences Group in the 3rd quarter valued at approximately $78,000. Virtu Financial LLC raised its holdings in shares of SELLAS Life Sciences Group by 24.1% in the third quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock valued at $99,000 after purchasing an additional 15,398 shares during the last quarter. State Street Corp grew its holdings in shares of SELLAS Life Sciences Group by 30.2% in the 3rd quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after acquiring an additional 40,500 shares in the last quarter. Finally, Opus Capital Group LLC increased its position in SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after buying an additional 12,400 shares during the last quarter. Institutional investors and hedge funds own 17.38% of the company's stock.

SELLAS Life Sciences Group Stock Down 0.7 %

SELLAS Life Sciences Group stock traded down $0.01 during trading hours on Wednesday, hitting $1.48. The stock had a trading volume of 593,301 shares, compared to its average volume of 4,840,785. The company has a market cap of $104.16 million, a PE ratio of -2.13 and a beta of 2.42. SELLAS Life Sciences Group has a fifty-two week low of $0.59 and a fifty-two week high of $1.84. The company has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.17.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.